<DOC>
	<DOCNO>NCT01456364</DOCNO>
	<brief_summary>Clopidogrel low response associate significantly high risk ischemic complication percutaneous coronary intervention . Ticagrelor prasugrel potent platelet inhibitory drug show significantly reduce ischemic event compare clopidogrel . No direct comparison ticagrelor prasugrel term antiplatelet efficacy exists . The aim study assess antiplatelet treatment efficacy ticagrelor versus prasugrel time confirm clopidogrel low responder undergo percutaneous coronary intervention .</brief_summary>
	<brief_title>Intracoronary Stenting Antithrombotic Regimen : ADjusting Antiplatelet Treatment PatienTs Based Platelet Function Testing</brief_title>
	<detailed_description />
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Prasugrel Hydrochloride</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<criteria>successful PCI 600 mg clopidogrel pretreatment clopidogrel low response assess electrode aggregometry ( &gt; = 486 AU*min ) write informed consent Contraindications allergy study drug Anemia Any surgery &lt; 6 week Increased bleed risk Oral anticoagulation platelet count &lt; 100.000/Âµl Prior history stroke pathologic intracranial finding GPIIb/IIIa antagonists &lt; 10 day periprocedural Age &gt; 80 year , &lt; 18 year Body weight &lt; 60 kg Cardiogenic shock Increased risk bradycardia Moderate liver disease Kidney dialysis Intake CYP 3A4 inhibitor Pregnancy lactation Missing pregnancy test woman capable bearing child</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>clopidogrel low response</keyword>
	<keyword>ticagrelor</keyword>
	<keyword>prasugrel</keyword>
	<keyword>platelet aggregation</keyword>
</DOC>